EQS-News: Eckert & Ziegler Extends Ga-68 Activities in Japan
EQS-News: Eckert Ziegler Strahlen- und Medizintechnik AG
/ Key word(s): Alliance/Study
Berlin, Germany – 28 February 2024 – Eckert Ziegler (ISIN DE0005659700, SDAX) expands its activities on Gallium-68 (Ga-68) labeled diagnostics in Japan together with Novartis Pharma K.K. (Japan). For this purpose, a clinical trial was notified with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA), stating Eckert Ziegler’s proprietary Ge-68/Ga-68 generator GalliaPharm® as the single source for Ga-68. The first GalliaPharm® as part of the study was delivered in January 2024 and will be followed by several further generators until mid-2025. The collaboration will generate considerable sales potential following successful market approval. “We are happy to extend our radioisotope supply business in Japan by contributing our GalliaPharm® to this important clinical research project,” explained Dr. Harald Hasselmann, CEO of Eckert Ziegler AG. “But much more importantly, the trial will set the basis for improved access to cancer therapies and diagnostics for Japanese patients.” The trial (NCT06240741) will investigate the diagnostic performance of [68Ga]Ga-DOTA-TATE Positron Emission Tomography (PET)/Computerized Tomography (CT) imaging in patients with neuroendocrine neoplasms (NEN). NEN are generally considered rare tumors. Yet the number of people diagnosed has been increasing globally for years. About Eckert Ziegler. Contact
28.02.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | Eckert Ziegler Strahlen- und Medizintechnik AG |
Robert-Rössle-Str.10 | |
13125 Berlin | |
Germany | |
Phone: | +49 30 941084-138 |
Fax: | +49 30 941084-112 |
E-mail: | [email protected] |
Internet: | www.ezag.de |
ISIN: | DE0005659700 |
WKN: | 565970 |
Indices: | SDAX, |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1846301 |
End of News | EQS News Service |
|
1846301 28.02.2024 CET/CEST
Eckert & Ziegler Strahlen- und Medizintechnik AG Stock
Eckert & Ziegler Strahlen- und Medizintechnik AG is currently one of the favorites of our community with 6 Buy predictions and no Sell predictions.
Based on the current price of 39.9 € the target price of 95 € shows a potential of 138.1% for Eckert & Ziegler Strahlen- und Medizintechnik AG which would more than double the current price.